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TREATMENT OF BACILLUS CALMETTE明GUERINREFRACTORY 
SUPERFICIAL BLADDER CANCER: FURTHER 
INTRA VESICAL THERAPY 
Yasuo KOH]IMOTO， Akinori IBA， Yasuyo SHINTANI， 
Yasunari UEKADO and Toshiaki SHINKA 
The Department 01 Urology， Uう7-kayamaMedical Univeηiり
We here report our clinical experience with salvage therapy for patients with bacillus Calmette-
Guerin (BCG)-refractory superficial bladder cancer and discuss current approaches to the disease， 
especially focusing on bladder preservation. First， we evaluated the efficacy of an initial ふweekcourse 
of intravesical BCG in 93 patients with carcinoma in situ (CIS) of the bladder. Of these， 91 % 
achieved a complete response (CR) at the evaluation at 3 months. The 2-and 5・yearrecurrence-free 
rates were 71 and 67%， respectively (mean follow-up 39 months). These results support the 
intravesical BCG as a first欄linetherapy for CIS. Next， we assessed the efficacy of a second course of 
intravesical BCG for 16 patients who failed the initial induction course for CIS. Ofthese， 94% achieved 
CR at the evaluation at 3-month， and the 2-and 5-year recurrence-free rates were 62 and 46%， 
respectively (mean follow-up 28 months). None of the patients who received a second course had 
disease progression. Thus， a second course of BCG therapy seems to be a reasonable option for CIS 
patients failing the initial course. 
We also report our initial experience with intravesical gemcitabine therapy for 3 patients with 
BCG-refractory CIS of the bladder and 1 patient with recurrent multiple tumors. Gemcitabine 
(1，500mg in 100ml saline) was given in the bladder for 1 hour twice weekly for a total of 12 treatments. 
The treatment was associated with minimal bladder irritation and systemic absorption， and was well 
tolerated except in a 90-year-old man who discontinued therapy because of grade 2 toxicity. Two 
patients achieved CR and maintained a tumor司freestatus beyond 14 months， suggesting that the 
intravesical gemcitabine is a promising salvage therapy for BCG-refractory superficial bladder cancer. 
(Hi町 okikaKiyo 51 : 533-538， 2005) 






































































害事象については， National Cancer Institute common 
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Kaplan-話eierprojected recurrence-free 
proportion of patients with CIS of the 
bladder after an initial course of intra-
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た，残存再発腫蕩の病理組織学的診断は， CIS: 10 











test， p = O.82; Fig. 2). BCG再注入療法が無効で
あった 7例の詳細を Table1に示す残存再発腫蕩
は， CIS: 5例， Tl， G3: 2例であった.このうち 3




Table I.Summaorf y i ofpatlents who failed SECond 
course of intravesical BCG therapy 
症例年齢再発腫蕩 治療 予後
77歳 CIS TUR-Bt + BCG勝 CR (3カ
Y玉 月)
2 80歳 CIS T注UR-Bt+ BCG勝 頻(44回カの月再)発
3 63歳 CIS BCG勝注 他カ月因)死 (1 
4 74歳 CIS ゲムシタピン勝注 治療中
5 71歳 TIG3 ゲムシタピン勝注 治療中
6 70歳 CIS ブロ全ピ摘リミン内服→ 癌(9なし生存勝脱 除術 3カ月)





(1)患者背景および腫蕩背景 (Table2) : 4例すべ
てが男性で，平均年齢は78.3歳 (66-85歳)であっ
た. 1例は原発性 CIS，2例は CISとTl腫蕩の合併






























なっている6，7) 腸耽 CISに対する BCG療法の近接
効果は約70%とされているがト7) われわれの93例の
Table 2. Summary of patients with high-risk superficial bladder cancer treated with intravesical gemcitabine 
therapy 
既往 治療効果 (3カ月)
症例 年齢 腫蕩形態・数 病理組織 予後
TUR-Bt BCG勝注 細胞診 勝脱鏡
85歳 発赤のみ TIG3+CIS 5回 3コー ス 陰性 異常なし 再発なし(15カ月)
2 66歳 発赤のみ CIS 4図 4コー ス 陰性 異常なし 再発なし(14カ月)
3 90歳 手L頭状・ 8個 T1G2+CIS 3回 2コー ス 陰性 乳頭状・ 3個
4 72歳 乳頭状・ 171固 TaG2 2回 なし 陰性 乳頭状・ 4個

































































































要であろう.例えば， Tl， G3腫蕩に随伴する diffuse
CIS症例は後に進展をきたす危険性がきわめて高い
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